Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10160MR)

This product GTTS-WQ10160MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10160MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11199MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ4219MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ15213MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ13103MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ9726MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ8505MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ6952MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ13687MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW